Chris Franklin (1), Lorenzo Ridolfi (1), Oscar Della Pasqua (1)
Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT
Objectives: Among the various objectives of the DDMoRe consortium, the development of a simplified modelling language is envisaged which will allow users to specify the mathematical structure of models. This will be defined in a general manner, allowing the use of different modelling tools. Here we show how the proposed modelling framework can be embedded within an existing modelling and simulation environment and identify how such concepts can benefit model-based drug development activities in R&D.
Methods: Using GlaxoSmithKline's current computer architecture and modelling environment as basis for a change impact analysis, we delineate how hardware, software, workflow, computing capacity and systems interconnectivity will be affected by the availability of a modelling language. In addition to the traceability and dependency of requirements and specifications, our analysis also evaluates how the proposed changes will affect operations and user community.
Results: Our change impact analysis reveals that the modifications required to incorporate DDMoRe concepts into a new environment are limited. These changes represent however potentially major challenges to standard business process and workflow. A change management programme needs to be considered to ensure that new process is taken up in an effective manner.
Conclusions: The acceptability of a new environment within an established business community has been appraised. The impact on business efficiency depends on the availability of translators and connectors suitable for the current software and on the implementation of an early change management program.
References:
[1] The DDMoRe Consortium http://www.ddmore.eu/
Reference: PAGE 22 () Abstr 2841 [www.page-meeting.org/?abstract=2841]
Poster: Other Modelling Applications